AVENUE THERAPEUTICS, INC. (ATXI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US05360L3042
AVENUE THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.40 m USD |
| Operating income | -3.08 m USD |
| EBIT | -3.07 m USD |
| Net income | -2.91 m USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About AVENUE THERAPEUTICS, INC.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
More stocks
- Kaya Holdings, Inc. (KAYS)
- Adagio Medical Holdings, Inc. (ADGM)
- GPO Plus, Inc. (GPOX)
- Ocean Thermal Energy Corp (CPWR)
- Sirius Media (ALSRS.PA)
- Odyssey Health, Inc. (ODYY)
- Catheter Precision, Inc. (VTAK)
- Lunai Bioworks Inc. (LNAI)
- Mentor Capital, Inc. (MNTR)
- ProtoKinetix, Inc. (PKTX)
- Athena Bitcoin Global (ABIT)
- Protagenic Therapeutics, Inc.\new (PTIX)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.